What Eye Problems Can HUVS Cause, and When Is It Urgent?
At a Glance
Hypocomplementemic urticarial vasculitis can cause conjunctivitis, episcleritis, scleritis, or uveitis. Severe eye pain, a painful red eye with reduced vision, sudden vision changes, or new flashes and floaters need urgent assessment. Hydroxychloroquine users need separate retinal screening.
Hypocomplementemic urticarial vasculitis (HUVS) is a rare condition that can cause inflammation in various parts of the eye. Because some forms of eye inflammation can damage vision quickly if left untreated, it is important to recognize the symptoms and seek prompt medical care [1][2].
An important reality of HUVS is that skin findings may not reliably reflect ocular (eye) involvement [3]. Case reports have shown that chronic eye inflammation, such as uveitis, can sometimes appear even before the characteristic urticarial rash and systemic symptoms of HUVS become fully evident [3]. You should not assume that a mild skin rash means your eyes are safe from inflammation.
Types of Eye Inflammation in HUVS
HUVS can affect different structures of the eye. The specific diagnosis depends on which part of the eye is inflamed:
- Conjunctivitis: Inflammation of the conjunctiva, the clear membrane that covers the white part of your eye and the inside of your eyelids [4]. While often called “pink eye,” in HUVS this is caused by inflammation rather than a contagious infection [5].
- Episcleritis: Inflammation of the episclera, a thin layer of tissue just beneath the conjunctiva [6]. This condition is usually superficial, mild, and self-limiting [7].
- Scleritis: Inflammation of the sclera, the deep, tough white outer wall of the eye [6][8]. Scleritis is more severe than episcleritis. It typically causes deep, severe eye pain and requires prompt treatment to prevent permanent damage to your eye and vision [2][9].
- Uveitis: Inflammation of the uvea, the middle layer of the eye that contains many blood vessels [3][10]. Uveitis can occur in the front (anterior), middle, or back of the eye, and untreated uveitis can lead to vision loss [11].
Estimates of how common these eye problems are can vary. In one small Swedish study of 16 patients with HUVS, 19% (about 1 in 5) had episcleritis or scleritis at the time they were diagnosed [6]. Keep in mind that a red or painful eye can also be caused by infections, allergies, or trauma. Never use leftover steroid eye drops for a new eye issue unless directed by an eye doctor, as steroids can worsen some infections.
When to Seek Emergency vs. Urgent Care
You should not wait for your next routine rheumatology appointment if you develop new eye symptoms. Depending on the severity, you may need immediate emergency care or a same-day urgent assessment from an ophthalmologist (a medical doctor who specializes in eye care).
Seek IMMEDIATE Emergency Care (Go to an emergency department if an eye doctor cannot see you immediately) for:
- Sudden vision loss or rapidly worsening vision [12]
- A shadow or “curtain” falling over your field of vision [13]
- A painful red eye accompanied by reduced vision [14][1]
- The sudden appearance of new floaters (spots or cobwebs) along with flashes of light [13]
Seek SAME-DAY Urgent Care (Call an eye doctor for a same-day appointment) for:
- Severe or deep-aching eye pain [2]
- Marked or sudden redness in one or both eyes [14]
- Increased sensitivity to light (where light actually hurts your eyes, known as photophobia) [1]
When you visit the eye doctor, they will likely check your visual acuity (how well you see letters on a chart) and eye pressure. They will use a microscope called a slit lamp to evaluate the front parts of your eye for inflammatory cells [1][15]. To examine the back of your eye (the posterior segment), they will give you drops to dilate your pupils and may use specialized imaging to look for deeper complications [16].
HUVS Eye Disease vs. Hydroxychloroquine Screening
If your doctor has prescribed hydroxychloroquine (often sold under the brand name Plaquenil) for your HUVS, you will need a specific type of eye screening. Monitoring for HUVS-related eye inflammation is very different from screening for hydroxychloroquine toxicity.
- HUVS Eye Checks: These exams look for active inflammation (like scleritis or uveitis) caused by the disease itself, as described above [1].
- Hydroxychloroquine Retinal Screening: Hydroxychloroquine can, over time, cause damage to the retina (the light-sensitive layer at the back of the eye) [17]. This toxicity can be silent and cause permanent vision loss before you notice any symptoms [18][19].
According to guidelines from the American Academy of Ophthalmology, patients starting hydroxychloroquine should have a baseline retinal exam soon after treatment begins [17][20]. Future annual specialized screening—which includes painless scans like Optical Coherence Tomography (OCT) and automated visual field testing to check for blind spots—depends on your risk factors [17].
Your risk is based on factors such as your daily dose calculated by your actual body weight, how long you have taken the medication, your kidney function (such as having chronic kidney disease), and whether you take the drug tamoxifen [17][21]. For standard-risk patients, annual screening might not begin until after 5 years of treatment, but higher-risk patients may need to start earlier [17][20].
Always make sure your eye doctor knows your exact hydroxychloroquine dose, how long you’ve been on it, and if you have any kidney issues. Do not stop taking your medication without discussing it with your prescribing doctor first [22].
Common questions in this guide
What eye problems can hypocomplementemic urticarial vasculitis cause?
Can HUVS affect my eyes before the skin rash appears?
Which HUVS eye symptoms require emergency care?
How does an eye doctor check for HUVS-related inflammation?
Is hydroxychloroquine retinal screening the same as checking for HUVS eye inflammation?
When should I start regular eye screening if I take hydroxychloroquine?
Can I use leftover steroid eye drops for a new red eye?
Related questions
Show more
Get notified when new evidence is published on Hypocomplementemic urticarial vasculitis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (22)
- 1
Inflammatory Eye Disease and Immunosuppressive Therapy: A Rheumatologist's Perspective.
Aung T
Cureus 2026; (18(9)):e116847 doi:10.7759/cureus.116847.
PMID: 42927373 - 2
[Diagnostic and Therapeutic Management of Episcleritis and Scleritis].
Turgut F, Dingerkus V, Tappeiner C, Becker M
Klinische Monatsblatter fur Augenheilkunde 2023; (240(5)):725-738 doi:10.1055/a-2022-0689.
PMID: 36827997 - 3
A case report of hypocomplementemic urticarial vasculitis presenting with membranoproliferative glomerulonephritis.
Vallianou K, Skalioti C, Liapis G, et al.
BMC nephrology 2020; (21(1)):351 doi:10.1186/s12882-020-02001-6.
PMID: 32811472 - 4
Hypocomplementemic Urticarial Vasculitis Syndrome Masquerading as Systemic Lupus Erythematosus: A Case Report.
Mehta JP, Jang CQH, Fahim P, et al.
Glomerular diseases 2022; (2(4)):189-193 doi:10.1159/000525942.
PMID: 36817292 - 5
A deep dive into monogenic lupus: insights on DNASE1L3 mutation.
Abdwani R, Mal MJ, Al Masroori E, et al.
Rheumatology (Oxford, England) 2025; (64(7)):4331-4334 doi:10.1093/rheumatology/keae679.
PMID: 39666950 - 6
Epidemiology of hypocomplementaemic urticarial vasculitis (anti-C1q vasculitis).
Sjöwall C, Mandl T, Skattum L, et al.
Rheumatology (Oxford, England) 2018; (57(8)):1400-1407 doi:10.1093/rheumatology/key110.
PMID: 29718374 - 7
[Scleritis and episcleritis].
Perray L, Ungerer L, Chazal T, et al.
La Revue de medecine interne 2023; (44(12)):646-655 doi:10.1016/j.revmed.2023.05.013.
PMID: 37344292 - 8
Hypocomplementemic urticarial vasculitis syndrome presenting with bilateral scleritis.
Berry EC, Wells J, Morey A, Anantharajah A
BMJ case reports 2021; (14(5)) doi:10.1136/bcr-2020-240041.
PMID: 33972296 - 9
Etanercept-associated episcleritis: a pediatric case report of a paradoxical adverse reaction and review of the literature.
Küçükali B, Gezgin Yıldırım D, Esmeray Şenol P, et al.
Clinical rheumatology 2024; (43(2)):799-808 doi:10.1007/s10067-023-06793-4.
PMID: 37845415 - 10
Rare presentation of hypocomplementaemic urticarial vasculitis syndrome (HUVS) overlapping with systemic erythematosus lupus (SLE) and small lymphocytic lymphoma (SLL).
Chao C, Aksoy M, Varma N, Tagoe CE
BMJ case reports 2025; (18(2)) doi:10.1136/bcr-2024-262329.
PMID: 39933844 - 11
Profile of adalimumab and its potential in the treatment of uveitis.
Balevic SJ, Rabinovich CE
Drug design, development and therapy 2016; (10()):2997-3003 doi:10.2147/DDDT.S94188.
PMID: 27698552 - 12
NODULAR POSTERIOR SCLERITIS: Clinico-Sonographic Characteristics and Proposed Diagnostic Criteria.
Agrawal R, Lavric A, Restori M, et al.
Retina (Philadelphia, Pa.) 2016; (36(2)):392-401 doi:10.1097/IAE.0000000000000699.
PMID: 26296144 - 13
Clinical features of infectious uveitis in a Tunisian population.
Maamouri R, Beldi M, Houman Y, et al.
La Tunisie medicale 2023; (101(2)):259-265.
PMID: 37682270 - 14
[Diagnosis and treatment approach for necrotizing scleritis (NS): A clinical case].
Hernández-Camarena JC, Rodríguez-García A, Valdez-García J
Gaceta medica de Mexico 2015; (151(4)):525-8.
PMID: 26290030 - 15
Acute Iridocyclitis Associated With Intravenous Zoledronic Acid: A Case Report.
Ankireddypalli AR, Sibley S
Cureus 2023; (15(8)):e43162 doi:10.7759/cureus.43162.
PMID: 37692746 - 16
Visual Morbidity and Outcomes of Scleritis Associated with Intraocular Inflammation Compared to Isolated Scleritis.
Liao A, Fajoles-Vasseneix C, Rali A, et al.
Ocular immunology and inflammation 2024; (32(6)):947-954 doi:10.1080/09273948.2022.2164726.
PMID: 36780586 - 17
Special AAO Report: Recommendations on Screening for Hydroxychloroquine Retinopathy (2025 Revision).
Marmor MF, Ahn SJ, Ehlers JP, et al.
Ophthalmology 2026; (133(4)):439-450 doi:10.1016/j.ophtha.2025.11.001.
PMID: 41232611 - 18
Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.
Leung LS, Neal JW, Wakelee HA, et al.
American journal of ophthalmology 2015; (160(4)):799-805.e1.
PMID: 26189086 - 19
Case Report: Hydroxychloroquine Retinopathy.
Eldeeb M, Chan EW, Omar A
Optometry and vision science : official publication of the American Academy of Optometry 2018; (95(6)):545-549 doi:10.1097/OPX.0000000000001226.
PMID: 29787487 - 20
American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity.
Rosenbaum JT, Costenbader KH, Desmarais J, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2021; (73(6)):908-911 doi:10.1002/art.41683.
PMID: 33559327 - 21
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Marmor MF, Kellner U, Lai TY, et al.
Ophthalmology 2016; (123(6)):1386-94.
PMID: 26992838 - 22
Target in Sight: A Comprehensive Review of Hydroxychloroquine-Induced Bull's Eye Maculopathy.
Snow Z, Seely K, Barrett S, et al.
Current ophthalmology reports 2024; (12(3)):38-48 doi:10.1007/s40135-024-00321-6.
PMID: 39371107
This page is for informational purposes only and does not constitute medical advice. An ophthalmologist and your HUVS clinician should evaluate new eye symptoms and advise you about hydroxychloroquine screening.